MP

Michael Perry

AVITA Medical, Inc. | Chief Executive Officer
Mr Perry was appointed Chief Executive Officer and Executive Director in June 2017. He continues to serve in this role. Prior to this appointment, Dr Perry served as a Non-Executive Director commencing in February 2013. From 2016 to 2017, he served as Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a U.S. affiliate of Switzerland-based Novartis AG. Dr Perry previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early-stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, a life science investment firm managing 41 venture capital funds, based in San Francisco California. Dr Perry serves as a Director of Arrowhead Pharmaceuticals, a public (NASDAQ) development stage company focused on medicines that treat intractable diseases by silencing genes. He is also a Venture Partner at BioScience Managers Pty Ltd.

Company and Role

Company
Title
Tenure
Since
AVH
AVITA Medical, Inc.
  • Chief Executive Officer
11yrs, 5mthFeb 2013

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
AVH
AVITA Medical, Inc.
13/12/22229,4992,9806,900N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
AVH
AVITA Medical, Inc.
13/12/22
Cancelled
13,800$2.100$28,980Cancellation of securities
AVH
AVITA Medical, Inc.
22/11/22
Buy
150,000$2.100$315,000Exercise of options
AVH
AVITA Medical, Inc.
22/11/22
Exercise
150,000$2.100$315,000Exercise of options
AVH
AVITA Medical, Inc.
22/11/22
Sell
150,000$7.180$1,077,000On-market trade
AVH
AVITA Medical, Inc.
28/09/22
Cancelled
59,560$1.685$100,358Cancellation of securities